Pharmacological actions of curcumin in liver diseases or damage

Research output: Contribution to journalScientific review

95 Citations (Scopus)

Abstract

Since 1900 BC, several therapeutic activities have been attributed to the rhizomes of the plant Curcuma longa for a variety of diseases, including liver disorders. Curcumin, the main active compound obtained from this plant, was first isolated two centuries ago and its structure as diferuloylmethane was determined in 1910. Curcumin has shown anti-inflammatory, anti-oxidant, antifungal, antibacterial and anticancer activities. The pharmacological properties of curcumin were reviewed recently and focused mainly on its anticancer properties. However, its beneficial activity on liver diseases (known centuries ago, and demonstrated recently utilizing animal models) has not being reviewed in depth until now. The curcumin ability to inhibit several factors like nuclear factor-κB, which modulates several pro-inflammatory and profibrotic cytokines as well as its anti-oxidant properties, provide a rational molecular basis to use it in hepatic disorders. Curcumin attenuates liver injury induced by ethanol, thioacetamide, iron overdose, cholestasis and acute, subchronic and chronic carbon tetrachloride (CCl4) intoxication; moreover, it reverses CCl4 cirrhosis to some extent. Unfortunately, the number of studies of curcumin on liver diseases is still very low and investigations in this area must be encouraged because hepatic disorders constitute one of the main causes of worldwide mortality. © 2009 John Wiley & Sons A/S.
Original languageAmerican English
Pages (from-to)1457-1466
Number of pages1310
JournalLiver International
DOIs
StatePublished - 1 Jan 2009
Externally publishedYes

Fingerprint

Curcumin
Liver Diseases
Pharmacology
Oxidants
Liver
Thioacetamide
Curcuma
Rhizome
Carbon Tetrachloride
Cholestasis
Fibrosis
Anti-Inflammatory Agents
Ethanol
Iron
Animal Models
Cytokines
Mortality
Wounds and Injuries

Cite this

@article{e5320d35323c4b48bd4f082d511260e0,
title = "Pharmacological actions of curcumin in liver diseases or damage",
abstract = "Since 1900 BC, several therapeutic activities have been attributed to the rhizomes of the plant Curcuma longa for a variety of diseases, including liver disorders. Curcumin, the main active compound obtained from this plant, was first isolated two centuries ago and its structure as diferuloylmethane was determined in 1910. Curcumin has shown anti-inflammatory, anti-oxidant, antifungal, antibacterial and anticancer activities. The pharmacological properties of curcumin were reviewed recently and focused mainly on its anticancer properties. However, its beneficial activity on liver diseases (known centuries ago, and demonstrated recently utilizing animal models) has not being reviewed in depth until now. The curcumin ability to inhibit several factors like nuclear factor-κB, which modulates several pro-inflammatory and profibrotic cytokines as well as its anti-oxidant properties, provide a rational molecular basis to use it in hepatic disorders. Curcumin attenuates liver injury induced by ethanol, thioacetamide, iron overdose, cholestasis and acute, subchronic and chronic carbon tetrachloride (CCl4) intoxication; moreover, it reverses CCl4 cirrhosis to some extent. Unfortunately, the number of studies of curcumin on liver diseases is still very low and investigations in this area must be encouraged because hepatic disorders constitute one of the main causes of worldwide mortality. {\circledC} 2009 John Wiley & Sons A/S.",
author = "Yadira Rivera-Espinoza and Pablo Muriel",
year = "2009",
month = "1",
day = "1",
doi = "10.1111/j.1478-3231.2009.02086.x",
language = "American English",
pages = "1457--1466",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",

}

Pharmacological actions of curcumin in liver diseases or damage. / Rivera-Espinoza, Yadira; Muriel, Pablo.

In: Liver International, 01.01.2009, p. 1457-1466.

Research output: Contribution to journalScientific review

TY - JOUR

T1 - Pharmacological actions of curcumin in liver diseases or damage

AU - Rivera-Espinoza, Yadira

AU - Muriel, Pablo

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Since 1900 BC, several therapeutic activities have been attributed to the rhizomes of the plant Curcuma longa for a variety of diseases, including liver disorders. Curcumin, the main active compound obtained from this plant, was first isolated two centuries ago and its structure as diferuloylmethane was determined in 1910. Curcumin has shown anti-inflammatory, anti-oxidant, antifungal, antibacterial and anticancer activities. The pharmacological properties of curcumin were reviewed recently and focused mainly on its anticancer properties. However, its beneficial activity on liver diseases (known centuries ago, and demonstrated recently utilizing animal models) has not being reviewed in depth until now. The curcumin ability to inhibit several factors like nuclear factor-κB, which modulates several pro-inflammatory and profibrotic cytokines as well as its anti-oxidant properties, provide a rational molecular basis to use it in hepatic disorders. Curcumin attenuates liver injury induced by ethanol, thioacetamide, iron overdose, cholestasis and acute, subchronic and chronic carbon tetrachloride (CCl4) intoxication; moreover, it reverses CCl4 cirrhosis to some extent. Unfortunately, the number of studies of curcumin on liver diseases is still very low and investigations in this area must be encouraged because hepatic disorders constitute one of the main causes of worldwide mortality. © 2009 John Wiley & Sons A/S.

AB - Since 1900 BC, several therapeutic activities have been attributed to the rhizomes of the plant Curcuma longa for a variety of diseases, including liver disorders. Curcumin, the main active compound obtained from this plant, was first isolated two centuries ago and its structure as diferuloylmethane was determined in 1910. Curcumin has shown anti-inflammatory, anti-oxidant, antifungal, antibacterial and anticancer activities. The pharmacological properties of curcumin were reviewed recently and focused mainly on its anticancer properties. However, its beneficial activity on liver diseases (known centuries ago, and demonstrated recently utilizing animal models) has not being reviewed in depth until now. The curcumin ability to inhibit several factors like nuclear factor-κB, which modulates several pro-inflammatory and profibrotic cytokines as well as its anti-oxidant properties, provide a rational molecular basis to use it in hepatic disorders. Curcumin attenuates liver injury induced by ethanol, thioacetamide, iron overdose, cholestasis and acute, subchronic and chronic carbon tetrachloride (CCl4) intoxication; moreover, it reverses CCl4 cirrhosis to some extent. Unfortunately, the number of studies of curcumin on liver diseases is still very low and investigations in this area must be encouraged because hepatic disorders constitute one of the main causes of worldwide mortality. © 2009 John Wiley & Sons A/S.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=73349116573&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=73349116573&origin=inward

U2 - 10.1111/j.1478-3231.2009.02086.x

DO - 10.1111/j.1478-3231.2009.02086.x

M3 - Scientific review

C2 - 19811613

SP - 1457

EP - 1466

JO - Liver International

JF - Liver International

SN - 1478-3223

ER -